Is Rezolute Inc. (RZLT) One of the Top Long-Term Biotechnology Stocks to Buy

Rezolute Inc. (NASDAQ:RZLT) is one of the top long-term biotechnology stocks to buy. Wedbush analyst Yun Zhong reaffirmed a Buy rating on Rezolute Inc. (NASDAQ:RZLT) stock on October 23, citing strong confidence in the company’s lead candidate, ersodetug.

Currently in Phase 3 trials for congenital hyperinsulinism (cHI), the drug has shown promise in addressing a significant unmet need through its novel insulin receptor-blocking mechanism. Zhong also highlighted Rezolute’s favorable competitive position, with ersodetug poised to gain substantial market share if approved. Additional opportunities in related conditions, such as tumor-induced hypoglycemia, further support a positive long-term outlook for the company.

Rezolute Inc. (NASDAQ:RZLT) is a biopharmaceutical company that develops therapies for rare and metabolic diseases. Its primary focus is on creating treatments for hyperinsulinism (HI), a rare genetic disorder that can cause dangerously low blood sugar, with its lead candidate being ersodetug.

While we acknowledge the potential of RZLT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Billionaire Steve Cohen’s 10 Small-Cap Stock Picks with Huge Upside Potential and Top 9 Credit Services Stocks to Buy as the US Cuts Interest Rates.

Disclosure: None. This article is originally published at Insider Monkey.